Statins: balancing benefits, efficacy and safety

Bibliography

• AMERICAN HEART ASSOCIATION: 2001 Heart and Stroke Statistical Update. American Heart Association, Dallas, Texas (2000).
   Google Scholar
• CASTELLI WP: Epidemiology of coronary heart disease: the Framingham study. Am. J. Med. (1984) 76(2A):4–12.
   Google Scholar
• Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA (1993) 269(23):3015–3023.
   PubMed Web of Science ®Google Scholar
• STAMLER J, WENTWORTH D, NEATON JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA (1986) 256(20):2823–2828.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344(8934):1383–1389.
   PubMed Web of Science ®Google Scholar
• ••Landmark trial demonstrating the benefitsof statins in reducing the risk for CHD.
   Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl. J. Med. (1996) 335(14):1001–1009.
   Google Scholar
• DOWNS JR, CLEARFIELD M, WETS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. "AMA (1998) 279(20):1615–1622.
   Google Scholar
• THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl. J. Med. (1998) 339(19):1349–1357.
   PubMed Web of Science ®Google Scholar
• GORDON DJ: Cholesterol lowering and total mortality. In: Lowering Cholesterol M High-Rick Individuals and Populations Rifkind BM (Ed.) Marcel Dekker, New York (1995):33–48.
   Google Scholar
• HEBERT PR, GAZIANO JM, CHAN KS, HENNEKENS CH: Cholesterol lowering with statin drugs, risk of stroke and total mortality. An overview of randomized trials. "AMA (1997) 278(4):313–321.
   Google Scholar
• PEARSON TA, LAURORA I, CHU H, KAFONEK S: The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. (2000) 160(4):459–467.
   PubMed Web of Science ®Google Scholar
• ••Key study showing that a large proportion of patients are not achieving NCEP-ATP II LDL-C target levels, highlighting the need for more aggressive treatment of dyslipidemia.
   Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). "AMA (2001) 285(19):2486–2497.
   PubMed Web of Science ®Google Scholar
• ••Recently revised NCEP guidelines, whichshow that a greater number of Americans should be receiving lipid-lowering therapy.
   Google Scholar
• Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. (1988) 148(1):36–69.
   Google Scholar
• SAFEER RS, LACIVITA CL: Choosing drug therapy for patients with hyperlipidemia. Am. Fam. Physician (2000) 61(11):3371–3382.
   PubMed Web of Science ®Google Scholar
• KNOPP RH: Drug therapy: drug treatment of lipid disorders. N Engl. J. Med. (1999) 341(7):498–511.
   PubMed Web of Science ®Google Scholar
• •General review article covering various treatments for dyslipidemia, including statins, bile acid binding resins, nicotinic acid and fibrates.
   Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl. J. Med. (1995) 333(20):1301–1307.
   PubMed Web of Science ®Google Scholar
• COLLINS R, PETO R, ARMITAGE J, OWEN OG: The MRC/BHF Heart Protection Study: preliminary results. Int. J. Gin. Pratt (2002) 56(1):53–56.
   PubMed Web of Science ®Google Scholar
• ••Largest trial of statin therapy everconducted, demonstrating that simvastatin 40 mg resulted in significant reductions of major vascular events irrespective of age, gender, cholesterol level, prior CHD, prior PVD and diabetes.
   Google Scholar
• ALBERT MA, DANIELSON E, RIFAI N, RIDKER PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. The PRINCE Investigators. "AMA (2001) 4286:64–70.
   Google Scholar
• RIDKER PM, RIFAI N, PFEFFER MA et al.: Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events Trial Investigators. Circulation (1998) 98:839–844.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, RIFAI N, PFEFFER MA, SACKS F, BRAUNWALD E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 100(3):230–235.
   Google Scholar
• RIDKER PM, RIFAI N, CLEARFIELD M et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl. J. Med. (2001) 344:1959–1965.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, RIFAI N, LOWENTHAL SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation (2001) 103:1191–1193.
   PubMed Web of Science ®Google Scholar
• HAY JW, YU WM, ASHRAF T: Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. PharmacoEconomics (1999) 15:47–74.
   PubMed Web of Science ®Google Scholar
• •General review of the pharmacoeconomics of statins and other lipid-lowering agents.
   Google Scholar
• CHONG PH, SEEGER JD, FRANKLIN C: Clinically relevant differences between the statins: implications for therapeutic selection. Am. J. Med. (2001) 111:390–400.
   PubMed Web of Science ®Google Scholar
• PICKIN DM, MCCABE CJ, RAMSAY LE et al.: Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart (1999) 82:325–332.
   PubMed Web of Science ®Google Scholar
• ASHRAF T, HAY JVV, PITT B et al: Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am. J. Cardiol (1997) 78:409–414.
   Web of Science ®Google Scholar
• JOHANNESSON M, JONSSON B, KJEKSHUS J, OLSSON AG, PEDERSEN TR, WEDEL H: Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl. J. Med. (1997) 336:332–336.
   Web of Science ®Google Scholar
• CARO J, KLITTICH W, MCGUIRE A, FORD I, NORRIE J, PETTITT D, MCMURRAY J, SHEPHERD J: The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin. Br. Med. I (1997) 315:1577–1582.
   PubMedGoogle Scholar
• TENGS TO, ADAMS ME, PLISKIN JS et al.: Five-hundred life-saving interventions and their cost-effectiveness. Rick Anal. (1995) 15:369–390.
   PubMed Web of Science ®Google Scholar
• •Wide-ranging assessment of the cost-effectiveness of 587 life-saving interventions, including statin therapy, CABG and angioplasty.
   Google Scholar
• HOERGER TJ, BALA MV, BRAY JVV, WILCOSKY TC, LAROSA JC: Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am. J. Cardiol. (1998) 82:61–65.
   PubMed Web of Science ®Google Scholar
• FEDDER DO, KORO CE, L'ITALIEN GJ: New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex and age distribution of the treatment-eligible population. Circulation (2002) 105:152–156.
   PubMed Web of Science ®Google Scholar
• •• Analysis of the new NCEP III guidelines,highlighting the need to provide a greater number of younger and elderly patients with aggressive lipid-lowering therapy.
   Google Scholar
• ANDRADE SE, SAPERIA GM, BERGER ML, PLATT R: Effectiveness of antihypertensive drug management in clinical practice. Clin.Ther: (1999) 21:1973–1987.
   Google Scholar
• ERHARDT LR: The essence of effective treatment and compliance is simplicity. Am. Hypertens. (1999) 12 (10, Pt 2):1055-110S.
   Google Scholar
• Choice of lipid-lowering drugs. Med. Lett. Drugs Ther. (1998) 40 (1042):117–122.
   Google Scholar
• FARMER IA, TORRE-AMIONE G: Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Sal (2000) 23(3):197–213.
   PubMed Web of Science ®Google Scholar
• FURBERG CD, PITT B: Withdrawal of cerivastatin from the world market. Curl: Control Trials Cardiovasc. Med. (2001) 2:205–207.
   PubMedGoogle Scholar
• DRESSER GK, SPENCE JD, BAILEY DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. OM. Pharmacokinet. (2000) 38 (1):41–57.
   PubMed Web of Science ®Google Scholar
• CORSINI A, BELLOSTA S, BAETTA R, FUMAGALLI R, PAOLETTI R, BERNINI F: New insights into the pharmacodynamic and pharmacokinetic properties of statins. PharmacolTher: (1999) 84(3):413–428.
   PubMed Web of Science ®Google Scholar
• KAJINAMI K, KOIZUMI J, UEDA K, MIYAMOTO S, TAKEGOSHI T, MABUCHI H: Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group. Am. j Cardiol (2000) 85(2):178–183.
   Google Scholar
• • Early study results for a new statin, NK-104, in 30 patients, showing that this agent is well-tolerated and that its potency is dose-dependent in patients with heterozygous FH.
   Google Scholar
• OLSSON AG, PEARS J, MCKELLAR J, MIZAN J, RAZA A: Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Jim. J Cardiol (2001) 88:504–508.
   Web of Science ®Google Scholar
• DAVIDSON M, MAP, STEIN EA et al.: Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with Type IIa or IIb hypercholesterolemia. Jim. .1 Cardiol (2002) 89:268–274.
   Google Scholar
• •Clinical trial results comparing the efficacy of a new statin, rosuvastatin, with atorvastatin in 516 patients, showing that rosuvastatin was associated with greater LDL-C reductions and HDL-C increases than atorvastatin.
   Google Scholar
• OLSSON A, SOUTHWORTH H, WIPHSHAARJW: Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator controlled trial versus atorvastatin. Eur. Heart J. (2001) 22 (Suppl.):253. Abstract 1410.
   Google Scholar
• PAOLETTI R, FAHMY M, MAHLA G, MIZAN J, SOUTHWORTH H: Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesteroleamic patients: a randomized, double-blind study. J Cardiovasc. Risk. (2001) 8(6):383–390.
   PubMedGoogle Scholar
• BROWN WV, CHITRA RR, ZEDLER BK, BAYS HE, HASSMAN HA: Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus pravastatin and simvastatin. Ear: Heart J. (2001) 22 (Suppl.):270. Abstract P1526.
   Google Scholar